Immunic Inc. Stock
Immunic Inc. Stock
A loss of -1.010% shows a downward development for Immunic Inc..
The stock is one of the favorites of our community with 23 Buy predictions and 1 Sell predictions.
Based on the current price of 0.58 € the target price of 8 € shows a potential of 1288.89% for Immunic Inc. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Immunic Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Immunic Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Immunic Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Immunic Inc. | -1.010% | -6.341% | -8.861% | -49.826% | -43.027% | -55.105% | -96.160% |
| NanoViricides Inc. | 8.990% | 0.980% | -39.412% | -23.134% | -31.333% | -34.206% | -66.558% |
| Actinium Pharmaceuticals Inc. | -2.260% | 0.000% | 4.526% | 5.608% | 6.342% | -88.529% | -86.324% |
| Ocuphire Pharma Inc. | -1.770% | 12.400% | 3.379% | 82.649% | 76.396% | -35.740% | - |
Comments
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at HC Wainwright from $10.00 to $8.00. They now have a "buy" rating on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic (NASDAQ:IMUX) had its price target lowered by analysts at D. Boral Capital from $10.00 to $8.00. They now have a "buy" rating on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
Immunic (NASDAQ:IMUX) is now covered by analysts at Roth Capital. They set a "buy" rating and a $3.00 price target on the stock.
Show more
Ratings data for IMUX provided by MarketBeat
News
EQS-News: Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
EQS-News: Immunic to Participate in the 8th Annual Evercore ISI Healthcare Conference in December
EQS-News: Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
EQS-News: Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
EQS-News: Immunic to Participate in Industry and Investor Conferences in November
EQS-News: Immunic to Participate in Industry and Investor Conferences in November